Outcomes of research biopsies in phase I clinical trials: The MD Anderson cancer center experience

Oncologist

Volumn 16, Issue 9, 2011, Pages 1292-1298

  El Osta, Hazem ^a   Hong, David ^a   Wheler, Jennifer ^a   Fu, Siqing ^a   Naing, Aung ^a   Falchook, Gerald ^a   Hicks, Marshall ^a   Wen, Sijin ^a   Tsimberidou, Apostolia M ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Drug development; Mandatory biopsy; Optional biopsy; Phase I clinical trial; Research biopsy

Indexed keywords

ANTITHROMBOCYTIC AGENT; ENOXAPARIN; HEPARIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CANCER CENTER; CONTROLLED STUDY; EXPERIENCE; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPOTENSION; LIVER BIOPSY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMOTHORAX; PRIORITY JOURNAL; RESEARCH BIOPSY; SAFETY; SKIN INFECTION; SUPRAVENTRICULAR TACHYCARDIA; TUBE; ULTRASOUND;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053196189     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0043     Document Type: Article

References (21)

1. Horstmann E, McCabe MS, Grochow L et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
2. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation:theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-4034.
3. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-720.
4. Peppercorn J, Shapira I, Collyar D et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol 2010;28:2635-2640.
5. Dowlati A, Haaga J, Remick SC et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res 2001;7:2971-2976.
6. West J, Card TR. Reduced mortality rates following elective, percutaneous liver biopsies. Gastroenterology 2010;139:1230-1237.
7. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol 2010;28:2925-2935.
8. Helft PR, Daugherty CK. Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol 2006;24:4793-4795.
9. Daugherty C, Ratain MJ, Grochowski E et al. Perceptions ofcancer patients and their physicians involved in phase I trials. J Clin Oncol 1995;13:1062-1072.
10. Nurgat ZA, Craig W, Campbell NC et al. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 2005;92:1001-1005.
11. Kodish E, Stocking C, Ratain MJ et al. Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons. J Clin Oncol 1992;10:1810-1816.
12. Plecha DM, Goodwin DW, Rowland DY et al. Liver biopsy: effects of biopsy needle caliber on bleeding and tissue recovery. Radiology 1997;204: 101-104.
13. Jain RK, Lee JJ, Hong D et al. Phase I oncology studies: evidence thatin the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-1297.
14. Yeow KM, Su IH, Pan KT et al. Risk factors of pneumothorax and bleed-ing:multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest 2004;126:748-754.
15. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-2726.
16. Agulnik M, Oza AM, Pond GR et al. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 2006;24:4801-4807.
17. Ranjan S, Chandra P, Prabhu S. Antidepressant-induced bruxism: need for buspirone? Int J Neuropsychopharmacol 2006;9:485-487.
18. Cox AC, Fallowfield LJ, Jenkins VA. Communication and informed consent in phase 1 trials: a review of the literature. Support Care Cancer 2006; 14:303-309.
19. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
20. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
21. Chabner BA. New results will change the paradigm for phase I trials and drug approval. The Oncologist 2010;15:1023-1025.